The historical data trend for RemeGen Co's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:REG vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, RemeGen Co's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RemeGen Co Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RemeGen Co's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where RemeGen Co's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
RemeGen Co (FRA:REG) has a Buyback Yield % of -1.25 as of Jul. 11, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on RemeGen Co and its competitors. According to the industry distribution chart, RemeGen Co ranks #215 out of 742 companies in the Biotechnology industry, placing it in the top 29%.
Is RemeGen Co's Buyback Yield % too high?
RemeGen Co's current Buyback Yield % is -1.25. Based on the distribution chart, RemeGen Co ranks #215 out of 742 companies in the Biotechnology industry, which is above the industry midpoint. Overall, RemeGen Co has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does RemeGen Co's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RemeGen Co ranks #215 out of 742 companies for Buyback Yield %. This puts RemeGen Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on RemeGen Co and its competitors. RemeGen Co's current Buyback Yield % is -1.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RemeGen Co stock overvalued right now?
Based on GuruFocus' analysis, RemeGen Co (FRA:REG) is currently considered Possible Value Trap. The stock's GF Value™ is €21.08, compared to a current price of €9.36 — trading 55.6% below its estimated fair value. The current Buyback Yield % is -1.25. RemeGen Co's overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For RemeGen Co (FRA:REG), the current Buyback Yield % is -1.25 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RemeGen Co (FRA:REG) Overvalued in 2026?
Based on GuruFocus' analysis, RemeGen Co stock appears to be undervalued.
The current stock price of €9.36 is trading 55.6% below its estimated GF Value™ of €21.08.
GuruFocus considers RemeGen Co to be Possible Value Trap.
Key valuation signals for FRA:REG:
Buyback Yield %: -1.25
GF Value™: €21.08 vs. price of €9.36 (55.6% below fair value)
No single metric tells the full story. See the FRA:REG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of biopharmaceuticals. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. The company's products are mainly used to treat severe diseases such as autoimmune diseases, oncology, and ophthalmology. It has its operations in China and the USA and derives the majority of its revenue from China.
39GF Score
Get the complete analysis for FRA:REG
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:REG has been successfully added to your 
